BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23734661)

  • 1. Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex.
    Florova G; Karandashova S; Declerck PJ; Idell S; Komissarov AA
    Biochemistry; 2013 Jul; 52(27):4697-709. PubMed ID: 23734661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
    Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
    J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.
    Florova G; Azghani AO; Karandashova S; Schaefer C; Yarovoi SV; Declerck PJ; Cines DB; Idell S; Komissarov AA
    Am J Physiol Lung Cell Mol Physiol; 2018 Jan; 314(1):L54-L68. PubMed ID: 28860148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of exosites 1 and 2 in thrombin reaction with plasminogen activator inhibitor-1 in the absence and presence of cofactors.
    Rezaie AR
    Biochemistry; 1999 Nov; 38(44):14592-9. PubMed ID: 10545182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
    Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
    Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
    Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
    J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
    Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
    Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.
    Podor TJ; Singh D; Chindemi P; Foulon DM; McKelvie R; Weitz JI; Austin R; Boudreau G; Davies R
    J Biol Chem; 2002 Mar; 277(9):7529-39. PubMed ID: 11744725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.
    Seiffert D; Ciambrone G; Wagner NV; Binder BR; Loskutoff DJ
    J Biol Chem; 1994 Jan; 269(4):2659-66. PubMed ID: 7507927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
    Debrock S; Declerck PJ
    Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis.
    Lawrence DA; Palaniappan S; Stefansson S; Olson ST; Francis-Chmura AM; Shore JD; Ginsburg D
    J Biol Chem; 1997 Mar; 272(12):7676-80. PubMed ID: 9065424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
    Whitley BR; Church FC
    Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.
    Schousboe SL; Egelund R; Kirkegaard T; Preissner KT; Rodenburg KW; Andreasen PA
    Thromb Haemost; 2000 May; 83(5):742-51. PubMed ID: 10823273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases.
    Debrock S; Declerck PJ
    FEBS Lett; 1995 Dec; 376(3):243-6. PubMed ID: 7498551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function.
    Chavakis T; Pixley RA; Isordia-Salas I; Colman RW; Preissner KT
    J Biol Chem; 2002 Sep; 277(36):32677-82. PubMed ID: 12082110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical importance of glycosylation of plasminogen activator inhibitor-1.
    Gils A; Pedersen KE; Skottrup P; Christensen A; Naessens D; Deinum J; Enghild JJ; Declerck PJ; Andreasen PA
    Thromb Haemost; 2003 Aug; 90(2):206-17. PubMed ID: 12888867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.